Skip to main content
. 2017 Oct 13;7:13151. doi: 10.1038/s41598-017-13638-z

Figure 2.

Figure 2

YC-1 ameliorates peritoneal inflammation in vivo. (a) Representative CD45 immunostainings (left) and histomorphometric quantification (right) of leukocytes within ischemic buttons of mice pretreated with YC-1 or vehicle (Ctrl), seven days after adhesion induction. (b) Representative F4/80 immunostainings (left) and histomorphometric quantification (right) of macrophages within ischemic buttons of mice pretreated with YC-1 or vehicle (Ctrl). Asterisks in (a,b) indicate positions of sutures (extracted) within ischemic buttons (see also Supplementary Fig. 5; HPF high power field; *P ≤ 0.05, n = 7 in (a,b). Scale bars = 200 μm. (c,d) ELISA of IL-6 (c) and TNFα (d) in tissue lysates of ischemic buttons, harvested 24 h after adhesion induction from Ctrl- and YC-1-treated animals (*P ≤ 0.05, n = 5) (e) ELISA-based quantification of IL-6 levels in peritoneal lavage fluid, harvested 24 h after adhesion induction (*P ≤ 0.05, n = 6). (f,g) Antibody array, revealing the relative abundance of M1- (f) and M2-macrophage-associated cytokines (g) in peritoneal fluid of mice pretreated with YC-1 or vehicle (Ctrl), one day after adhesion induction (***P ≤ 0.001, n = 4; ANOVA with Bonferroni post-hoc tests).